Table 2.
Monocyte and PMN phenotypes
| Phenotype | Patients with AAV | Healthy controls | P value |
|---|---|---|---|
| Monocytes (% of leukocytes) | 4.4 ± 0.3 | 4.8 ± 0.24 | n.s. |
| (109/L, reference range <1,1) | 0.33 ± 0.02 | ||
| Lymphocytes (% of leukocytes) | 20 ± 1.2 | 31 ± 1.2 | <0.0001 |
| (109/L, reference range 1.1–4.8) | 0.74 ± 0.05 | ||
| PMN (% of leukocytes) | 39 ± 1.3 | 28 ± 1.1 | <0.0001 |
| (109/L, reference range 1.7–8.0) | 5.9 ± 0.3 | ||
| CD16+CD10+ (% of PMN) | 84 ± 1.1 | 82 ± 1.2 | n.s. |
| CD16dimCD10- (% of PMN) | 8.9 ± 0.8 | 6.8 ± 0.6 | 0.0109 |
| CD177+ (% of PMN) | 55 ± 2.4 | 47 ± 1.9 | 0.0075 |
| CD10+CD16+ PMN | |||
| CD88+ (geoMFI) | 442 ± 14 | 409 ± 15 | n.s |
| CD62L+ (geoMFI) | 1,277 ± 37 | 1,269 ± 41 | n.s. |
| CD11c+(geoMFI) | 558 ± 14 | 596 ± 16 | n.s |
| CD10+CD16dim PMN | |||
| CD88+ (geoMFI) | 391 ± 8.2 | 381 ± 7.6 | n.s |
| CD62L+ (geoMFI) | 450 ± 23 | 457 ± 22 | n.s |
| CD11c+(geoMFI) | 354 ± 7.2 | 428 ± 10 | <0.0001 |
| Monocytes | |||
| CD88+ (geoMFI) | 162 ± 2.5 | 165 ± 2.5 | n.s |
| CD62L+ (geoMFI) | 770 ± 29 | 651 ± 37 | <0.0001 |
| CD11c+(geoMFI) | 1,645 ± 63 | 2,079 ± 78 | <0.0001 |
The frequencies of monocytes, lymphocytes, polymorphonuclear leukocytes (PMN), CD10+CD16+ (mainly segment nucleated neutrophils) and CD10-CD16dim (suggested as a marker for newly released neutrophils) were investigated in healthy controls (n = 109) and patients (n = 105) using flow cytometry. In addition, the level of surface expression of CD88 (C5aR), CD62L and CD11c was studied on CD10+ CD16+ PMN, CD10 + CD16dim PMN and monocyte populations, as a measurement of activation and reported as geometric mean fluorescence intensity (geoMFI). The two-sided Mann-Whitney test was used to calculate the level of significance. Values are reported as mean ± SEM. AAV anti-neutrophil cytoplasmic antibodies associated vasculitides, n.s. not significant